Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
•
Neuro-infectious disease
When do you consider pembrolizumab for the treatment of progressive multifocal leukoencephalopathy?
Related Questions
What is your disease modifying treatment of choice for a patient with relapsing remitting multiple sclerosis with treated, well controlled HIV?
Do you recommend surveillance lumbar punctures for patients with Mollaret's meningitis after diagnosis or in between clinical episodes?
How do you balance the risk of unnecessary treatment with acyclovir against the risk of delaying treatment in encephalitis cases where CSF pleocytosis is absent?
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?
What criteria do you use to differentiate between MOGAD and MS in pediatric patients?
How do you handle medication management for patients on immunosuppressive therapy who are lost to follow-up?
Do you have any clinical experience regarding the administration of B cell depleting therapies in MS patients with splenectomy?
How do you interpret CSF pleocytosis in the context of significant leukocytosis on CBC?
In a patient with prior biopsy-proven IgG4-related pachymeningitis who develops recurrent neurologic symptoms years after discontinuing immunosuppression, how do you determine whether this represents relapse versus alternative etiologies?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
